MEG3 and breast carcinoma: MEG3 interacts with the PRC2 complex and suppresses the expression of genes involved in the TGF-β pathway, such as TGFB2, TGFBR1, and SMAD2, in human breast cancer cells [30], thus inhibiting the SMAD-dependent signaling pathway.